Autres langues Oncternal Therapeutics, Inc.

Actions

ONCT

US68236P2065

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 23/04/2024			Varia. 5j.	Varia. 1 janv.
8,765 ^USD	+2,51 %		+0,86 %	-18,27 %

18/04	Oncternal annonce que le premier patient a été traité dans la quatrième cohorte de l'étude de phase 1/2 de l'ONCT-534 pour le traitement du cancer de la prostate métastatique résistant à la castration.	CI
15/04	ONCTERNAL THERAPEUTICS, INC. : HC Wainwright reste à l'achat	ZM

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18/04
Oncternal Announces First Patient Dosed in Fourth Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	18/04
Oncternal Participating in Virtual Fireside Chat with Key Opinion Leader on Treatment Landscape & New Treatment Options for Prostate Cancer	15/03
Oncternal Therapeutics: Q4 Earnings Snapshot	07/03
Oncternal Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Oncternal Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07/03
Oncternal Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results	07/03
Oncternal Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results	29/02
Oncternal Therapeutics to Participate in Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	01/02
Oncternal Therapeutics, Inc. Appoints Damien Bresson as Senior Director, Preclinical and Translation Science	01/02
Oncternal Therapeutics Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08/01
Oncternal Therapeutics, Inc. Enrolls Patients into the Third Dosing Cohort of its Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer	08/01
Oncternal Therapeutics Announces Reverse Stock Split	04/01
Oncternal Therapeutics Reports Inducement Award under Nasdaq Listing Rule 5635(4)	03/01
Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	02/01
Traders Look Ahead to Flat Day After Post-Christmas Rally	27/12
Top Premarket Decliners	27/12
Sector Update: Health Care Stocks Stronger Late Afternoon	26/12
Sector Update: Health Care Stocks Steady Tuesday Afternoon	26/12

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Oncternal Therapeutics, Inc.

Actions

ONCT

US68236P2065

Autres langues

Filtres